EBX-002
EBX-002 FOR NON-TUBERCULOUS MYCOBACTERIAL LUNG INFECTIONS
Relapse of NTM Infection is Common and Eradication Difficult:
90000
ESTIMATED US NTM PREVALENCE
69
PERCENT OF PATIENTS 65 OR OLDER
18
MONTHS OF ANTIBIOTIC TREATMENT
- NTM is a chronic, debilitating disease generating significant morbidity and mortality
- NTM more prevalent than TB in the US
- Highest incidence growth among patients aged 65+, a population expected to double by 2030
EBX-002 for NTM Treatment:
EBX-002 is a combination of amikacin (AMK) and a potentiator molecule (PTN) expected to be a superior treatment for persistent NTM infections versus amikacin alone. EBX-002 significantly enhances killing of bacterial persisters through a novel mechanism. Data already generated show >4 logs of enhanced killing of M. avium persisters with EBX-002 versus AMK alone.
Sales of currently approved inhaled amikacin products grew to $160M in 2020, less than two years after FDA approval. EBX-002 would offer a superior product at a competitive price
